recombinant erythropoietin stimulating proteins   Published February 2017  •  Catalog no. ESP434F17 •  Price US $1,850



Each year, an estimated 1.2 million cancer patients undergo cytotoxic chemotherapy in the United States; and approximately 800,000 (67%) will become anemic. ESPs, a type of hematopoietic agent, stimulate the bone marrow to increase the production of red blood cells and have been shown to result in a clinically significant improvement of anemia associated with chemotherapy. Total global revenue for recombinant ESP drugs was slightly approximately six billion USD in 2016. Recombinant ESP drugs are one of the first class of protein drugs to feel the effects of biosimilars. Slightly less than half of the branded drugs in this class are biosimilars. This report examines each recombinant ESPs in detail and forecasts the effects of the uptake of biosimilars on the global recombinant ESP market.

Bar_GraphReport Brochure (Download PDF)

Blue documentReport Order Form (Download PDF)


Recombinant Erythropoietin Stimulating Proteins – What You Will Learn

• What are the recombinant ESP products that are have been given marketing authorization by the FDA or the EMA?
• Who supplies the API; the finished product? Who is the labeler; the marketer? What is the host system?
• Who are the major recombinant ESP suppliers; what are their facilities, and where are they located?
• What are the as-supplied characteristics for each ESP product and how are they administered?
• What is the probable impact of biosimilars on approved ESP products in North America; in Europe?
• What does the market look like today? What is the forecast for how it will look in 2022?
• What will be the impact of economic, technology, and regulatory factors on the commercial potential of recombinant ESPs?


Recombinant Erythropoietin Stimulating Proteins – Summary of Contents

Executive Summary

Recombinant ESPs – The Market Opportunity

Treating Anemia
Therapeutic Demand Drivers
Demographic Factors
Competitive Landscape
Risk Factors

Sourcing Recombinant ESPs

API
Final Product
Labeler
Supplier Ecosystem
Collaborations & Relationships

Recombinant ESPs – Indications & Markets

Anemia
Chemotherapy-induced Anemia
Anemia due to CKD
Pre-donation of Autologous Blood

Recombinant ESPs– Product Analysis

Abseamed
Aranesp
Binocrit
Biopoin
Epoetin Alfa Hexal
Epogen
Eporatio
Mircera
NeoRecormon
Procrit
Retacrit
Silapo

Recombinant ESPs – Market Data & Forecasts

Market Factors

Regulatory Issues
Packaging and Administration
Biosimilars
Managed Care Initiatives

Company Profiles